Market Research Logo

Vulvodynia Treatment Market: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

Vulvodynia Treatment Market: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

There is an increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives. According to the National Center for Biotechnology Information, U.S. National Library of Medicine, 17.9% of women reported symptoms suggestive of past Vulvodynia in 2013. Based on an analysis, 101,007 women in the 4-county area are estimated to have vulvar pain consistent with Vulvodynia, with another 218,219 having a history of such pain that has since resolved. As a result of these factors, the demand for the drugs is constantly rising. The drug type and its use is measured by the level of pain that is caused of vulvodynia. Although it is a chronic disease, at times even the minutest of pain can cause depression and anxiety among women.

Anticonvulsant to be the most used drug

Anticonvulsant is a type of medication that is used for controlling seizures or stop an ongoing series of seizures (convulsions). In Vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which has long been recognized in chronic pain management as an effective way of curing pain. It contains tablets taken by mouth and works well for pain related to the nerve. The tablets are prescribed for a number of conditions impacting the central nervous system and they influence pain at the level of the spinal cord. Pregabalin is another anticonvulsant drug. It is very similar to gabapentin; however, it is reported to have fewer side effects and is possibly more operative. Tricyclic antidepressant to rise in consumption

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. These can be prescribed by your doctor in doses lower than those used to treat depression. The drugs are used because they alter the way in which the nerve fibres transmit the sensation of pain, not because the doctor thinks it's all in your mind. It is often necessary to continue with treatment for 3-6 months. Examples of tablets include amitriptyline, nortriptyline and dothiepin. Other antidepressants namely venlafaxine can also be tried. As the treatment of vulvodynia is mainly centred at placebo, antidepressants are the first of form of medical treatments given to a patient in case of minor pains.

Use of local anaesthetic to rise globally

Local anaesthetics are generally applied externally to the skin. This medication originates in a form of gel or cream. They may be used before sexual intercourse to provide short-term pain relief, or they can be used for extended periods. Local anaesthetic is used topically to introitus, which decrease hypersensitivity. This medication need to apply before intercourse or nightly on a cotton ball in the introitus. Lidocaine gel or cream is considered to be the best local anaesthetic cream or gel for vulvodynia.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Vulvodynia Treatment Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Occurrence of Vulvodynia
3.4. Regulatory Scenario
4. Vulvodynia Treatment Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
4.4. Trends
5. North America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
5.1. Introduction
5.2. Regional Market Dynamics
5.3. Historical Market Size (US$ Mn) By Country, 2013-2017
5.3.1. U.S.
5.3.2. Canada
5.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
5.4.1. U.S.
5.4.2. Canada
5.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
5.5.1. Anticonvulsant
5.5.2. Tricyclic Antidepressant
5.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
5.5.4. Hormone
5.5.5. Nerve Block
5.5.6. Local Anesthetic
5.5.7. Others
5.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
5.6.1. Anticonvulsant
5.6.2. Tricyclic Antidepressant
5.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
5.6.4. Hormone
5.6.5. Nerve Block
5.6.6. Local Anesthetic
5.6.7. Others
5.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
5.7.1. Oral
5.7.2. Topical
5.7.3. Injectable
5.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
5.8.1. Oral
5.8.2. Topical
5.8.3. Injectable
5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
5.9.1. Hospital Pharmacies
5.9.2. Retail Pharmacies
5.9.3. Drug Stores
5.9.4. Online Pharmacies
5.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
5.10.1. Hospital Pharmacies
5.10.2. Retail Pharmacies
5.10.3. Drug Stores
5.10.4. Online Pharmacies
5.11. Drivers and Restraints: Impact Analysis
5.12. Market Attractiveness Analysis
5.12.1. By Country
5.12.2. By Drug Class
5.12.3. By Mode Of Administration
5.12.4. By Distribution Channel
5.13. Key Representative Market Participants
5.14. Key Participants Market Presence (Intensity Map)
6. Latin America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
6.1. Introduction
6.2. Regional Market Dynamics
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
6.3.1. Brazil
6.3.2. Mexico
6.3.3. Rest of Latin America
6.4. Market Size (US$ Mn) Forecast By Country, 2018–2028
6.4.1. Brazil
6.4.2. Mexico
6.4.3. Rest of Latin America
6.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
6.5.1. Anticonvulsant
6.5.2. Tricyclic Antidepressant
6.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
6.5.4. Hormone
6.5.5. Nerve Block
6.5.6. Local Anesthetic
6.5.7. Others
6.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
6.6.1. Anticonvulsant
6.6.2. Tricyclic Antidepressant
6.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
6.6.4. Hormone
6.6.5. Nerve Block
6.6.6. Local Anesthetic
6.6.7. Others
6.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
6.7.1. Oral
6.7.2. Topical
6.7.3. Injectable
6.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
6.8.1. Oral
6.8.2. Topical
6.8.3. Injectable
6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
6.9.1. Hospital Pharmacies
6.9.2. Retail Pharmacies
6.9.3. Drug Stores
6.9.4. Online Pharmacies
6.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Drug Stores
6.10.4. Online Pharmacies
6.11. Drivers and Restraints: Impact Analysis
6.12. Market Attractiveness Analysis
6.12.1. By Country
6.12.2. By Drug Class
6.12.3. By Mode Of Administration
6.12.4. By Distribution Channel
6.13. Key Representative Market Participants
6.14. Key Participants Market Presence (Intensity Map)
7. Western Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Regional Market Dynamics
7.3. Historical Market Size (US$ Mn) By Country, 2013-2017
7.3.1. Germany
7.3.2. United Kingdom
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Nordic Region
7.3.7. Rest of Western Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
7.4.1. Germany
7.4.2. United Kingdom
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Nordic Region
7.4.7. Rest of Western Europe
7.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
7.5.1. Anticonvulsant
7.5.2. Tricyclic Antidepressant
7.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
7.5.4. Hormone
7.5.5. Nerve Block
7.5.6. Local Anesthetic
7.5.7. Others
7.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
7.6.1. Anticonvulsant
7.6.2. Tricyclic Antidepressant
7.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
7.6.4. Hormone
7.6.5. Nerve Block
7.6.6. Local Anesthetic
7.6.7. Others
7.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
7.7.1. Oral
7.7.2. Topical
7.7.3. Injectable
7.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
7.8.1. Oral
7.8.2. Topical
7.8.3. Injectable
7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
7.9.1. Hospital Pharmacies
7.9.2. Retail Pharmacies
7.9.3. Drug Stores
7.9.4. Online Pharmacies
7.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Drug Stores
7.10.4. Online Pharmacies
7.11. Drivers and Restraints: Impact Analysis
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Class
7.12.3. By Mode Of Administration
7.12.4. By Distribution Channel
7.13.Key Representative Market Participants
7.14.Key Participants Market Presence (Intensity Map)
8. Eastern Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Regional Market Dynamics
8.3. Historical Market Size (US$ Mn) By Country, 2013-2017
8.3.1. Russia
8.3.2. Poland
8.3.3. Rest of Eastern Europe
8.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
8.4.1. Russia
8.4.2. Poland
8.4.3. Rest of Eastern Europe
8.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
8.5.1. Anticonvulsant
8.5.2. Tricyclic Antidepressant
8.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
8.5.4. Hormone
8.5.5. Nerve Block
8.5.6. Local Anesthetic
8.5.7. Others
8.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
8.6.1. Anticonvulsant
8.6.2. Tricyclic Antidepressant
8.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
8.6.4. Hormone
8.6.5. Nerve Block
8.6.6. Local Anesthetic
8.6.7. Others
8.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
8.7.1. Oral
8.7.2. Topical
8.7.3. Injectable
8.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
8.8.1. Oral
8.8.2. Topical
8.8.3. Injectable
8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
8.9.1. Hospital Pharmacies
8.9.2. Retail Pharmacies
8.9.3. Drug Stores
8.9.4. Online Pharmacies
8.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Drug Stores
8.10.4. Online Pharmacies
8.11. Drivers and Restraints: Impact Analysis
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Class
8.12.3. By Mode Of Administration
8.12.4. By Distribution Channel
8.13. Key Representative Market Participants
8.14. Key Participants Market Presence (Intensity Map)
9. Asia Pacific Excluding Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Regional Market Dynamics
9.3. Historical Market Size (US$ Mn) By Country, 2013-2017
9.3.1. China
9.3.2. India
9.3.3. Australia and New Zealand
9.3.4. ASEAN
9.3.5. Rest of APEJ
9.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
9.4.1. China
9.4.2. India
9.4.3. Australia and New Zealand
9.4.4. ASEAN
9.4.5. Rest of APEJ
9.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
9.5.1. Anticonvulsant
9.5.2. Tricyclic Antidepressant
9.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
9.5.4. Hormone
9.5.5. Nerve Block
9.5.6. Local Anesthetic
9.5.7. Others
9.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
9.6.1. Local Anesthetic
9.6.2. Anticonvulsant
9.6.3. Tricyclic Antidepressant
9.6.4. Hormones
9.6.5. Serotonin-norepinephrine reuptake inhibitors (SNRI)
9.6.6. Nerve Block
9.6.7. Others
9.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
9.7.1. Oral
9.7.2. Topical
9.7.3. Injectable
9.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
9.8.1. Oral
9.8.2. Topical
9.8.3. Injectable
9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
9.9.1. Hospital Pharmacies
9.9.2. Retail Pharmacies
9.9.3. Drug Stores
9.9.4. Online Pharmacies
9.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Drug Stores
9.10.4. Online Pharmacies
9.11. Drivers and Restraints: Impact Analysis
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Mode Of Administration
9.12.4. By Distribution Channel
9.13. Key Representative Market Participants
9.14. Key Participants Market Presence (Intensity Map)
10. Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Regional Market Dynamics
10.3. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
10.3.1. Anticonvulsant
10.3.2. Tricyclic Antidepressant
10.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
10.3.4. Hormone
10.3.5. Nerve Block
10.3.6. Local Anesthetic
10.3.7. Others
10.4. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
10.4.1. Anticonvulsant
10.4.2. Tricyclic Antidepressant
10.4.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
10.4.4. Hormone
10.4.5. Nerve Block
10.4.6. Local Anesthetic
10.4.7. Others
10.5. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
10.5.1. Oral
10.5.2. Topical
10.5.3. Injectable
10.6. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
10.6.1. Oral
10.6.2. Topical
10.6.3. Injectable
10.7. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Drug Stores
10.7.4. Online Pharmacies
10.8. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Drug Stores
10.8.4. Online Pharmacies
10.9. Drivers and Restraints: Impact Analysis
10.10. Market Attractiveness Analysis
10.10.1. By Drug Class
10.10.2. By Mode Of Administration
10.10.3. By Distribution Channel
10.11. Key Representative Market Participants
10.12. Key Participants Market Presence (Intensity Map)
11. Middle East and Africa Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Regional Market Dynamics
11.2.1. Drivers
11.2.2. Restraints
11.2.3. Trends
11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017
11.3.1. GCC Countries
11.3.2. South Africa
11.3.3. Rest of MEA
11.4. Market Size (US$ Mn) Forecast By Country, , 2018–2028
11.4.1. GCC Countries
11.4.2. South Africa
11.4.3. Rest of MEA
11.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
11.5.1. Anticonvulsant
11.5.2. Tricyclic Antidepressant
11.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
11.5.4. Hormone
11.5.5. Nerve Block
11.5.6. Local Anesthetic
11.5.7. Others
11.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028
11.6.1. Anticonvulsant
11.6.2. Tricyclic Antidepressant
11.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
11.6.4. Hormone
11.6.5. Nerve Block
11.6.6. Local Anesthetic
11.6.7. Others
11.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
11.7.1. Oral
11.7.2. Topical
11.7.3. Injectable
11.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
11.8.1. Oral
11.8.2. Topical
11.8.3. Injectable
11.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
11.9.1. Hospital Pharmacies
11.9.2. Retail Pharmacies
11.9.3. Drug Stores
11.9.4. Online Pharmacies
11.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Drug Stores
11.10.4. Online Pharmacies
11.11. Drivers and Restraints: Impact Analysis
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Class
11.12.3. By Mode Of Administration
11.12.4. By Distribution Channel
11.13. Key Representative Market Participants
11.14. Key Participants Market Presence (Intensity Map)
12. Forecast Factors: Relevance and Impact
13. Forecast Assumptions
14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. GlaxoSmithKline plc.
14.2.2. AstraZeneca Plc.
14.2.3. Eli Lilly and Company
14.2.4. Merck & Co., Inc.
14.2.5. Pfizer Inc.
14.2.6. Johnson & Johnson Services, Inc.
14.2.7. Allergan plc.
14.2.8. Depomed Inc.
14.2.9. Par pharmaceutical
14.2.10. Vertical pharmaceutical
15. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Region, 2013–2017
15.2.1. North America
15.2.2. Western Europe
15.2.3. Eastern Europe
15.2.4. Latin America
15.2.5. Asia Pacific Excluding Japan
15.2.6. Japan
15.2.7. Middle East and Africa
15.3. Market Size (US$ Mn) Forecast By Region, 2018–2028
15.3.1. North America
15.3.2. Western Europe
15.3.3. Eastern Europe
15.3.4. Latin America
15.3.5. Asia Pacific Excluding Japan
15.3.6. Japan
15.3.7. Middle East and Africa
15.4. Key Trends / Developments
15.5. Market Attractiveness Analysis By Region
16. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
16.2.1. Anticonvulsant
16.2.2. Tricyclic Antidepressant
16.2.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
16.2.4. Hormone
16.2.5. Nerve Block
16.2.6. Local Anesthetic
16.2.7. Others
16.3. Market Size (US$ Mn) Forecast By Drug Class, 2018–2028
16.3.1. Anticonvulsant
16.3.2. Tricyclic Antidepressant
16.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
16.3.4. Hormone
16.3.5. Nerve Block
16.3.6. Local Anesthetic
16.3.7. Others
16.4. Market Attractiveness Analysis By Drug Class
17. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Mode Of Administration
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017
17.2.1. Oral
17.2.2. Topical
17.2.3. Injectable
17.3. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028
17.3.1. Oral
17.3.2. Topical
17.3.3. Injectable
17.4. Market Attractiveness Analysis By Mode Of Administration
18. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
18.2.1. Hospital Pharmacies
18.2.2. Retail Pharmacies
18.2.3. Drug Stores
18.2.4. Online Pharmacies
18.3. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028
18.3.1. Hospital Pharmacies
18.3.2. Retail Pharmacies
18.3.3. Drug Stores
18.3.4. Online Pharmacies
18.4. Market Attractive Analysis By Distribution Channel

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report